Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

University of Calgary

$135,000.00

A novel inhibitor of remyelination in multiple sclerosis: fibulin-2

EF 2020-21

Résumé
Multiple sclerosis (MS) is a disease in which the immune system destroys protective fatty protein (myelin) covering nerve fibers in the brain and spinal cord, leading to physical disability. A process by which myelin is reformed following injury called remyelination can restore physical function. Remyelination becomes increasingly incomplete and inefficient in most patients with age and longevity of dieases. This failure could be due to the presence of inhibitors in the lesion. We aim to explore these inhibitors to provide better treatments for MS patients. Although there are drugs available for the early stages of MS through modulation of immune system, there are no treatments that promote myelin formation and tissue repair. Therefore, identifying the inhibitors is important to develop a strategy to overcome their impact on myelin repair. Fibulin-2 is an extracellular matrix (ECM) protein that is accumulated in MS lesions. Our preliminary data show its toxic effect on oligodendrocyte precursor cells which are responsible for remyelination. In this proposal, I will assess the exact role of fibulin-2 in myelin repair and discover new therapeutic approaches to overcome the inhibitory effect of fibulin-2.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
440202
Name
Ghorbanigazar Samira
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
A novel inhibitor of remyelination in multiple sclerosis: fibulin-2
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Multiple Sclerosis; Remyelination
Abstract
Multiple sclerosis (MS) is a disease in which the immune system destroys protective fatty protein (myelin) covering nerve fibers in the brain and spinal cord, leading to physical disability. A process by which myelin is reformed following injury called remyelination can restore physical function. Remyelination becomes increasingly incomplete and inefficient in most patients with age and longevity of dieases. This failure could be due to the presence of inhibitors in the lesion. We aim to explore these inhibitors to provide better treatments for MS patients. Although there are drugs available for the early stages of MS through modulation of immune system, there are no treatments that promote myelin formation and tissue repair. Therefore, identifying the inhibitors is important to develop a strategy to overcome their impact on myelin repair. Fibulin-2 is an extracellular matrix (ECM) protein that is accumulated in MS lesions. Our preliminary data show its toxic effect on oligodendrocyte precursor cells which are responsible for remyelination. In this proposal, I will assess the exact role of fibulin-2 in myelin repair and discover new therapeutic approaches to overcome the inhibitory effect of fibulin-2.
Competitiondate
202012
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ghorbanigazar, Samira
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~